Physician Wealth Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Physician Wealth Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.65K	Hold	177	–	–	﹤0.01%	1381
2026 Q1	$2.59K	Hold	177	–	–	﹤0.01%	1241
2025 Q4	$1.36K	Hold	177	–	–	﹤0.01%	1462
2025 Q3	$1.3K	Buy	+177	New	+$906	﹤0.01%	1421

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Physician Wealth Advisors's CRVS Position: Q2 2026 in Review

Physician Wealth Advisors held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 177 shares worth $2.65K. The position accounts for ﹤0.01% of the portfolio, ranked #1381.

Physician Wealth Advisors first reported a position in CRVS in Q3 2025 and has held it in 4 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Physician Wealth Advisors held 177 shares of Corvus Pharmaceuticals worth $2.65K as of Q2 2026.
Physician Wealth Advisors left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
Corvus Pharmaceuticals made up ﹤0.01% of Physician Wealth Advisors's portfolio in Q2 2026, its #1381 holding.
Physician Wealth Advisors first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Physician Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.